Qingdao Baheal Medical INC.

SZSE:301015 Stock Report

Market Cap: CN¥12.2b

Qingdao Baheal Medical Future Growth

Future criteria checks 3/6

Qingdao Baheal Medical is forecast to grow earnings and revenue by 20.7% and 7.7% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 28.8% in 3 years.

Key information

20.7%

Earnings growth rate

20.6%

EPS growth rate

Healthcare earnings growth22.2%
Revenue growth rate7.7%
Future return on equity28.8%
Analyst coverage

Low

Last updated26 Jan 2025

Recent future growth updates

No updates

Recent updates

Many Would Be Envious Of Qingdao Baheal Medical's (SZSE:301015) Excellent Returns On Capital

Oct 21
Many Would Be Envious Of Qingdao Baheal Medical's (SZSE:301015) Excellent Returns On Capital

It's Down 25% But Qingdao Baheal Medical INC. (SZSE:301015) Could Be Riskier Than It Looks

Jun 30
It's Down 25% But Qingdao Baheal Medical INC. (SZSE:301015) Could Be Riskier Than It Looks

Qingdao Baheal Medical (SZSE:301015) Looks To Prolong Its Impressive Returns

Jun 21
Qingdao Baheal Medical (SZSE:301015) Looks To Prolong Its Impressive Returns

Qingdao Baheal Medical (SZSE:301015) Has Affirmed Its Dividend Of CN¥0.762

May 26
Qingdao Baheal Medical (SZSE:301015) Has Affirmed Its Dividend Of CN¥0.762

Qingdao Baheal Medical (SZSE:301015) Has A Rock Solid Balance Sheet

May 21
Qingdao Baheal Medical (SZSE:301015) Has A Rock Solid Balance Sheet

Many Would Be Envious Of Qingdao Baheal Medical's (SZSE:301015) Excellent Returns On Capital

Mar 01
Many Would Be Envious Of Qingdao Baheal Medical's (SZSE:301015) Excellent Returns On Capital

Earnings and Revenue Growth Forecasts

SZSE:301015 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202610,1791,284N/A1,0703
12/31/20259,0761,053N/A9293
12/31/20248,161854N/A7693
12/31/20237,889654N/A7754
9/30/20237,975703393531N/A
6/30/20237,414588377492N/A
3/31/20237,336537470589N/A
12/31/20227,510502200306N/A
9/30/20227,336458327411N/A
6/30/20227,436451264314N/A
3/31/20227,286423136170N/A
1/1/20227,052422154181N/A
9/30/20217,038421524543N/A
6/30/20216,797349210228N/A
3/31/20216,291303-66-51N/A
12/31/20205,879273-133-117N/A
12/31/20194,8492104043N/A
12/31/20183,6522583753N/A
12/31/20173,096222149160N/A
12/31/20163,034184N/A88N/A
12/31/20152,39273N/A82N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301015's forecast earnings growth (20.7% per year) is above the savings rate (2.8%).

Earnings vs Market: 301015's earnings (20.7% per year) are forecast to grow slower than the CN market (25% per year).

High Growth Earnings: 301015's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301015's revenue (7.7% per year) is forecast to grow slower than the CN market (13.3% per year).

High Growth Revenue: 301015's revenue (7.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301015's Return on Equity is forecast to be high in 3 years time (28.8%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 16:35
End of Day Share Price 2025/01/27 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qingdao Baheal Medical INC. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Wen DaiHuatai Research
Tielin ChenTopsperity Securities